New remedy for diabetes demonstrates good results in weight loss
Science Translational Medicine in the October 30 edition. The results still indicate a high potential for reversal of the metabolic syndrome
The mechanism of action of the new medication unites the effects of two hormones: GLP-1 and GIP. These two hormones, called incretin hormones, are released naturally in the intestine when we feed, and act on the pancreas stimulating insulin secretion, which will reduce blood glucose levels. There are already in the market injectable medications for type 2 diabetes with the effect of the hormone GLP-1, and that despite leading to weight loss, have side effects such as nausea or vomiting. However, there are no commercially available drugs that have the effects of GIP, and through scientific studies it is known that this hormone controls sugar levels, but does not lead to weight gain.
The advantage of the new medication, called of unimolecular incretinic double agonist (
unimolecular dual incretin co-agonist ) is to stimulate insulin production and reduce the production of glucagon, which is a hormone that increases glucose. Another effect is also to slow the emptying of the stomach after the meal, prolonging the sensation of satiety and, therefore, reducing the hunger. By having GIP hormone action, the new remedy improves the feeling of nausea. The results still indicate a high potential for reversal of the metabolic syndrome, which is when the diabetic presents obesity, high levels of cholesterol or triglycerides and associated high blood pressure. The results on weight loss in rats guinea pigs who made use of the new remedy are promising. A comparison was made between the two drugs: the first with GLP-1 action alone and the second, the new double-acting drug. In rats that received only the one with GLP-1 action there was loss of 15.4% of body weight, prevention of fat accumulation and reduction of food intake. In those who received the new drug, there was a 20.8% reduction in body weight, greater than the effect of GLP-1 alone.
Certainly, the dissemination of such promising results is excellent news. Diabetes is a disease with a great potential to cause complications such as blindness, kidney failure, myocardial infarction and amputations. The study of new medicines is essential to broaden the horizons of treatment, and all we need (and want to) hear is good news!
More than 1,000 patients participated in the study: 500 healthy subjects, 250 who had already undergone stroke and 250 who had coronary syndrome, a common type of heart disease that increases the chances of formation of blood clots in the arteries, strokes and heart attacks. Everyone completed a questionnaire about their sleeping and eating habits.
The fecal occult blood test, as the name says, looks at the presence of blood in the stool that can not be seen with the naked eye. A positive result for this test indicates that the patient is suffering from bleeding in the large intestine, which may be the result of inflammation, trauma or colorectal cancer.